Accendra Health says Q2 2026 results miss forecast on weaker revenue growth, slower collections recovery

• Accendra Health’s Q2 2026 results missed internal expectations, citing weaker-than-planned revenue growth, slower cost-save timing, slower collections recovery.
• Revenue excluding the large commercial payor exit rose 2%; sleep grew about 5.5%, diabetes 4%, while respiratory and wound declined.
• Adjusted EBITDA was just over $60 million; the collections “waterfall” reduced revenue and earnings by about $10 million in Q2, $20 million in H1.
• Accounts receivable rose as certain commercial insurers’ audit-related process issues slowed cash receipts; improvement efforts were trending toward resolution in Q3.
• Full-year outlook cut to revenue of $2.45 billion-$2.55 billion, adjusted EBITDA of $300 million-$320 million; free cash flow expected breakeven to slightly positive.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accendra Health Inc. published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.